Zhongyuan Union Cell & Gene Engineering Corporation Overview
- Status
-
Public
- Employees
-
2,209
- Stock Symbol
-
600645
- Investments
-
11
- Share Price
-
$2.63
- (As of Friday Closing)
Zhongyuan Union Cell & Gene Engineering Corporation General Information
Description
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
Contact Information
Website
www.vcanbio.comCorporate Office
- Room 406, No. 45 Doungjiu Avenue
- Tianjin Airport Economic Zone
- Tianjin, 300304
- China
Corporate Office
- Room 406, No. 45 Doungjiu Avenue
- Tianjin Airport Economic Zone
- Tianjin, 300304
- China
Zhongyuan Union Cell & Gene Engineering Corporation Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.63 | $2.55 | $1.81 - $3.05 | $1.23B | 468M | 7.78M | $0.03 |
Zhongyuan Union Cell & Gene Engineering Corporation Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 854,606 | 1,158,219 | 985,761 | 1,699,388 |
| Revenue | 221,491 | 224,700 | 230,882 | 237,774 |
| EBITDA | 34,258 | 34,986 | 41,050 | 52,622 |
| Net Income | 15,141 | 15,047 | 16,777 | 24,054 |
| Total Assets | 730,446 | 763,388 | 765,965 | 789,661 |
| Total Debt | 16,122 | 16,347 | 18,781 | 11,076 |
Zhongyuan Union Cell & Gene Engineering Corporation Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Zhongyuan Union Cell & Gene Engineering Corporation Executive Team (10)
| Name | Title | Board Seat |
|---|---|---|
| Yong Wang | Company Director and General Manager | |
| Wei He | Deputy General Manager | |
| Xuejun Wang | Deputy General Manager | |
| Yongjun Liu | Deputy General Manager | |
| Haifeng Cao | Director |
Zhongyuan Union Cell & Gene Engineering Corporation Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000000 000 | Self | Independent Director | 000 0000 |
| 000000000 000 | Self | Independent Director | 000 0000 |
Zhongyuan Union Cell & Gene Engineering Corporation Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Zhongyuan Union Cell & Gene Engineering Corporation Investments & Acquisitions (11)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Juventas Biology | 25-Jun-2023 | 00000 0000 | 0000 | Drug Discovery | |
| Precision Medicine Industry Innovation Center | 03-Aug-2022 | 000000000 | Biotechnology | ||
| Juventas Biology | 13-Dec-2018 | 00000 0000 | 000.00 | Drug Discovery | |
| Origene | 13-Feb-2017 | 0000000000 | Discovery Tools (Healthcare) | ||
| Genetron Health | 19-Sep-2016 | Early Stage VC | 000.00 | Diagnostic Equipment |
Zhongyuan Union Cell & Gene Engineering Corporation Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Origene | Discovery Tools (Healthcare) | Rockville, MD | 1996 |
| Shanghai Zhicheng Biotechnology | Other Pharmaceuticals and Biotechnology | Pudong, China | 0000 |
Zhongyuan Union Cell & Gene Engineering Corporation ESG
Risk Overview
Risk Rating
Updated April, 19, 2024
27.64 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Biotechnology
Subindustry
00 of 404
Rank
Percentile
Zhongyuan Union Cell & Gene Engineering Corporation Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Genetron Health | 19-Sep-2016 | 00000 00000 | 000.00 | Completed |
|
| Aeon Therapeutics | 01-Jan-2002 | Joint Venture | Completed |
|
Zhongyuan Union Cell & Gene Engineering Corporation FAQs
-
Where is Zhongyuan Union Cell & Gene Engineering Corporation headquartered?
Zhongyuan Union Cell & Gene Engineering Corporation is headquartered in Tianjin, China.
-
What is the size of Zhongyuan Union Cell & Gene Engineering Corporation?
Zhongyuan Union Cell & Gene Engineering Corporation has 2,209 total employees.
-
What industry is Zhongyuan Union Cell & Gene Engineering Corporation in?
Zhongyuan Union Cell & Gene Engineering Corporation’s primary industry is Biotechnology.
-
Is Zhongyuan Union Cell & Gene Engineering Corporation a private or public company?
Zhongyuan Union Cell & Gene Engineering Corporation is a Public company.
-
What is Zhongyuan Union Cell & Gene Engineering Corporation’s stock symbol?
The ticker symbol for Zhongyuan Union Cell & Gene Engineering Corporation is 600645.
-
What is the current stock price of Zhongyuan Union Cell & Gene Engineering Corporation?
As of 13-Sep-2024 the stock price of Zhongyuan Union Cell & Gene Engineering Corporation is $2.63.
-
What is the current market cap of Zhongyuan Union Cell & Gene Engineering Corporation?
The current market capitalization of Zhongyuan Union Cell & Gene Engineering Corporation is $1.23B.
-
What is Zhongyuan Union Cell & Gene Engineering Corporation’s current revenue?
The trailing twelve month revenue for Zhongyuan Union Cell & Gene Engineering Corporation is $221M.
-
What is Zhongyuan Union Cell & Gene Engineering Corporation’s annual earnings per share (EPS)?
Zhongyuan Union Cell & Gene Engineering Corporation’s EPS for 12 months was $0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
